Thrombin receptor

[4] There are species-specific differences in thrombin receptor expression in platelets and other cell types, [5] in which differences in thrombin concentrations may considerably affect...

Metabolism-based identification of a potent thrombin receptor antagonist

The metabolism of our prototypical thrombin receptor antagonist 1, Ki = 2.7 nM, was studied and three major metabolites (2, 4, and 5) were found. The structures of the metabolites were verified ind...

Thrombin receptors and their antagonists: an update on the patent literature

field: Thrombin plays a central role in cardiovascular inflammation. Most of the cellular responses to thrombin are mediated... of thrombin receptors antagonists. It is focused on the...

Direct thrombin inhibitor

Direct thrombin inhibitors (DTIs) are a class of medication that act as anticoagulants... ADP receptor/P2Y 12 inhibitors Thienopyridines Clopidogrel Prasugrel Ticlopidine Nucleotide...

Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent....

Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. by Samuel Chackalamannil, Yuguang Wang, William J Greenlee, Zhiyong...

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

*********.*******@****.*** Abstract Background: Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. Methods: In this...

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial:....

platelet receptor for thrombin, represents a novel target for treatment of arterial... PAR-1 antagonist. We designed TRA*CER to evaluate the efficacy and safety of SCH 530348 compared with...

US6017890A - Azole peptidomimetics as thrombin receptor antagonists

Worldwide applications ; 1999-02-08 · Application filed by Ortho McNeil Pharmaceutical Inc ; 1999-02-08 · Priority to US09/245,739 ; 1999-05-17 · Assigned to ORTHO-MCNEIL PHARMACEUTICAL, INC. ; 1999-09-01 · Priority to US09/387,489

Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Plate

We evaluated the interaction between protease-activated receptor-1 antagonist vorapaxar and concomitant glycoprotein (GP) IIb/IIIa receptor inhibitors in patients with non-ST-segment elevation acut...

In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist

Vorapaxar is a novel protease-activated receptor-1 (PAR1) antagonist recently approved for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or w...